

References

1. Long B, Carius BM, Chavez S, Liang SY, Brady WJ, Koyfman A, et al. Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation. *The American Journal of Emergency Medicine*. 2022 2022/04/01/;54:46-57. Available at: <https://www.sciencedirect.com/science/article/pii/S0735675722000304>
2. Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. *Proceedings of the National Academy of Sciences of the United States of America*. 2021 Aug 24;118(34)
3. Schulze H, Bayer W. Changes in Symptoms Experienced by SARS-CoV-2-Infected Individuals – From the First Wave to the Omicron Variant. *Frontiers in Virology*. 2022 2022-July-01;2 Available at: <https://www.frontiersin.org/articles/10.3389/fviro.2022.880707>
4. Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. *Journal of Internal Medicine*. 2020;288:335 - 44.
5. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. *MMWR Morbidity and mortality weekly report*. 2020 Jun 19;69(24):759-65.
6. Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. *Otolaryngology–Head and Neck Surgery*. 2020;163(1):3-11. Available at: <https://journals.sagepub.com/doi/abs/10.1177/0194599820926473>
7. Aziz M, Perisetti A, Lee-Smith WM, Gajendran M, Bansal P, Goyal H. Taste Changes (Dysgeusia) in COVID-19: A Systematic Review and Meta-analysis. *Gastroenterology*. 2020 2020/09/01/;159(3):1132-3. Available at: <https://www.sciencedirect.com/science/article/pii/S0016508520305953>
8. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. *Euro surveillance : bulletin European sur les maladies transmissibles = European communicable disease bulletin*. 2021 Dec;26(50)
9. UK Health Security Agency (UKHSA). SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 34. 2022 Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050236/technical-briefing-34-14-january-2022.pdf
10. Vihta K-D, Pouwels KB, Peto TE, Pritchard E, House T, Studley R, et al. Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. *medRxiv*. 2022:2022.01.18.22269082. Available at: <https://www.medrxiv.org/content/medrxiv/early/2022/05/18/2022.01.18.22269082.full.pdf>
11. Mantovani A, Rinaldi E, Zusi C, Beatrice G, Saccomani MD, Dalbeni A. Coronavirus disease 2019 (COVID-19) in children and/or adolescents: a meta-analysis. *Pediatric Research*. 2021 2021/03/01;89(4):733-7. Available at: <https://doi.org/10.1038/s41390-020-1015-2>
12. Raba AA, Abobaker A, Elgenaidi IS, Daoud A. Novel coronavirus infection (COVID-19) in children younger than one year: A systematic review of symptoms, management and outcomes. *Acta paediatrica (Oslo, Norway : 1992)*. 2020 Oct;109(10):1948-55.
13. Patel NA. Pediatric COVID-19: Systematic review of the literature. *American journal of otolaryngology*. 2020 Sep-Oct;41(5):102573.
14. Rajapakse N, Dixit D. Human and novel coronavirus infections in children: a review. *Paediatrics and international child health*. 2021 Feb;41(1):36-55.
15. Amit S, Beni SA, Biber A, Grinberg A, Leshem E, Regev-Yochay G. Postvaccination COVID-19 among Healthcare Workers, Israel. *Emerging infectious diseases*. 2021 Apr;27(4):1220-2.
16. Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital

- admissions, and mortality in older adults in England: test negative case-control study. *BMJ*. 2021;373:n1088. Available at: <https://www.bmj.com/content/bmj/373/bmj.n1088.full.pdf>
17. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *Jama*. 2020 Mar 17;323(11):1061-9.
 18. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis Research*. 2020 2020/07/01/;191:145-7. Available at: <https://www.sciencedirect.com/science/article/pii/S0049384820301201>
 19. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nature Medicine*. 2022 2022/03/01;28(3):583-90. Available at: <https://doi.org/10.1038/s41591-022-01689-3>
 20. Kartsonaki C. Characteristics and outcomes of an international cohort of 400,000 hospitalised patients with Covid-19. *medRxiv*. 2021:2021.09.11.21263419. Available at: <https://www.medrxiv.org/content/medrxiv/early/2021/09/21/2021.09.11.21263419.full.pdf>
 21. Public Health Ontario (PHO). COVID-19 in Ontario: Focus on January 2, 2022 to January 8. 2022 Available at: <https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-weekly-epi-summary-report.pdf?la=en>
 22. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. *medRxiv*. 2022:2022.01.11.22269045. Available at: <https://www.medrxiv.org/content/medrxiv/early/2022/01/11/2022.01.11.22269045.full.pdf>
 23. Christensen PA, Olsen RJ, Long SW, Snehal R, Davis JJ, Saavedra MO, et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston, Texas. *medRxiv*. 2022:2021.12.30.21268560. Available at: <https://www.medrxiv.org/content/medrxiv/early/2022/01/19/2021.12.30.21268560.full.pdf>
 24. Bager P, Wohlfahrt J, Bhatt S, Edslev SM, Sieber RN, Ingham AC, et al. Reduced risk of hospitalisation associated with infection with SARS-CoV-2 omicron relative to delta: a Danish cohort study. 2022
 25. Hyams C, Challen R, Nguyen J, Begier E, Southern J, King J, et al. Severity of Omicron (B. 1.1. 529) and Delta (B. 1.1. 617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study. *medRxiv*. 2022
 26. Bundle N, Dave N, Pharris A, Spiteri G, Deogan C, Suk JE. COVID-19 trends and severity among symptomatic children aged 0-17 years in ten EU countries, 3 August 2020 – 3 October 2021. *medRxiv*. 2021:2021.11.25.21266875. Available at: <https://www.medrxiv.org/content/medrxiv/early/2021/11/29/2021.11.25.21266875.full.pdf>
 27. World Health Organization (WHO). Multisystem inflammatory syndrome in children and adolescents with COVID-19. 2020 Available at: <https://www.who.int/publications/i/item/multisysteminflammatory-syndrome-in-children-and-adolescents-with-covid-19>
 28. Royal College of Paediatrics and Child Health (RCPCH). Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS) - guidance for clinicians. . 2020 Available at: <https://www.rcpch.ac.uk/resources/paediatric-multisysteminflammatory-syndrome-temporally-associated-covid-19-pims-guidance>
 29. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. *Jama*. 2020;324(3):259-69. Available at: <https://doi.org/10.1001/jama.2020.10369>
 30. World Health Organization (WHO). A clinical case definition of post COVID-19 condition by a Delphi consensus. 2021 Available at: <https://apps.who.int/iris/handle/10665/345824>

31. World Health Organization (WHO). Coronavirus disease (COVID-19): Post COVID-19 condition. 2021 Available at: [https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-\(covid-19\)-post-covid-19-condition](https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition)
32. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. medRxiv. 2020:2020.10.19.20214494. Available at: <https://www.medrxiv.org/content/medrxiv/early/2020/12/19/2020.10.19.20214494.full.pdf>
33. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Scientific reports. 2021;11(1):1-12.
34. Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. medRxiv. 2021:2021.06.28.21259452. Available at: <https://www.medrxiv.org/content/medrxiv/early/2021/07/03/2021.06.28.21259452.full.pdf>
35. Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. The Lancet Regional Health-Europe. 2021;6:100122.
36. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2021;397(10270):220-32.
37. Naik S, Haldar SN, Soneja M, Mundadan NG, Garg P, Mittal A, et al. Post COVID-19 sequelae: a prospective observational study from Northern India. Drug Discoveries & Therapeutics. 2021
38. Venturelli S, Benatti SV, Casati M, Binda F, Zuglian G, Imeri G, et al. Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation. Epidemiology & Infection. 2021;149
39. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in adults at 6 months after COVID-19 infection. JAMA network open. 2021;4(2):e210830-e.
40. Blomberg B, Mohn KG, Brokstad KA, Zhou F, Linchausen DW, Hansen BA, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021 Sep;27(9):1607-13.
41. Chen C, Hauptert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. The Journal of Infectious Diseases. 2022 Available at: <https://doi.org/10.1093/infdis/jiac136>
42. Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375(6585):1122-7. Available at: <https://www.science.org/doi/abs/10.1126/science.abm8108>
43. Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. bmj. 2022;377
44. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. The Lancet Infectious Diseases. 2022;22(1):43-55.
45. Zimmermann P, Pittet LF, Curtis N. How Common is Long COVID in Children and Adolescents? The Pediatric Infectious Disease Journal. 2021;40(12):e482-e7. Available at: https://journals.lww.com/pidj/Fulltext/2021/12000/How_Common_is_Long_COVID_in_Children_and_Adolescents.aspx
46. Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children—a nationwide cohort study. European journal of pediatrics. 2022;181(4):1597-607.
47. European Centre for Disease Prevention and Control (ECDC). Webinar on post-COVID-19 condition in children. 2021 Available at: <https://www.ecdc.europa.eu/en/news-events/webinar-post-covid-19-condition-children>